Roche, Amgen Agree on Temporary Mircera Import Ban

Roche has agreed not to oppose Amgen’s request for a limited exclusion order that would block the import of Roche’s anemia drug Mircera into the U.S. Amgen filed a motion recently with the U.S. International Trade Commission asking for a summary determination that Roche had violated a section of the Smoot-Hawley Tariff Act by importing the pegylated erythropoietin product Mircera (methoxy polyethylene glycol-epoetin beta), which Amgen claims infringes its patents.
Washington Drug Letter